Trial Filter

BETA

An intelligent search tool for clinical trials

Sign In
Back|NCT05998135Recruiting
Official Title

Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Phase
Phase 2
Sponsor
Emory University
Enrollment
28
Timeline
Nov 2023 → Jun 2027
About This Study

This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.

Eligibility Criteria

Inclusion Criteria

  • 1Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy
  • 2Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • 3There will be no limitations on number of prior lines of therapy
  • 4Trial is open to non-English speaking patients
  • 5Trial is open to patients referred from community practice

Exclusion Criteria

  • 1Patients who are \< 18 years old
  • 2Patients who are pregnant or breastfeeding (due to cancer of their reproductive organs, patients enrolled in the trial are unable to conceive)
  • 3Patients who are incarcerated
  • 4Patients who are unable to provide consent / lack decision-making capacity

Locations

1 site participating in this study

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia 30322

Recruiting

Namita Khanna, MD, MSPH

Data sourced from ClinicalTrials.govView on ClinicalTrials.gov →